» Articles » PMID: 10664627

HER-2/neu Protein Expression in Breast Cancer Evaluated by Immunohistochemistry. A Study of Interlaboratory Agreement

Overview
Specialty Pathology
Date 2000 Feb 9
PMID 10664627
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Immunohistochemistry (IHC) is used commonly for evaluating HER-2/neu protein expression in breast cancer. Given the potential clinical importance of HER-2/neu status in patient management, interlaboratory variability in HER-2/neu IHC results in a matter of legitimate concern. We compared the results from 2 laboratories for HER-2/neu determined by IHC on paraffin sections of the same 100 consecutive invasive breast cancers. Both laboratories used the same primary antibody; however, different methods for heat-induced epitope retrieval (microwave or steam) and immunostaining (automated equipment from different manufacturers) and different scoring systems (positive-negative and 0-4+) were used. Slides were read in a blinded fashion and the results from the 2 laboratories were compared. Of the 93 cases evaluable in both laboratories, 24% were scored as HER-2/neu-positive at 1 laboratory, and 23% were scored as positive at the other. Complete concordance in categorization of HER-2/neu status between the 2 laboratories was achieved in 90 of 93 cases. Excellent interlaboratory agreement for HER-2/neu IHC was attained using the same primary antibody to HER-2/neu, even without standardization of assay method or scoring criteria. However, standardization of these parameters remains an important objective to optimize interlaboratory agreement.

Citing Articles

Photoimmunotherapy of HER2-expressing Breast Cancer Cells.

Klemenz L, Wolf I, Storz J, Schultze-Seemann S, Gratzke C, Lauw S Cancer Genomics Proteomics. 2024; 21(4):361-367.

PMID: 38944426 PMC: 11215433. DOI: 10.21873/cgp.20453.


Clinical Proteomics for Solid Organ Tissues.

Phipps W, Kilgore M, Kennedy J, Whiteaker J, Hoofnagle A, Paulovich A Mol Cell Proteomics. 2023; 22(11):100648.

PMID: 37730181 PMC: 10692389. DOI: 10.1016/j.mcpro.2023.100648.


Accelerated instability testing reveals quantitative mass spectrometry overcomes specimen storage limitations associated with PD-L1 immunohistochemistry.

Haragan A, Liebler D, Das D, Soper M, Morrison R, Slebos R Lab Invest. 2020; 100(6):874-886.

PMID: 31896815 PMC: 7280177. DOI: 10.1038/s41374-019-0366-y.


Droplet digital PCR as an alternative to FISH for MYCN amplification detection in human neuroblastoma FFPE samples.

Somasundaram D, Aravindan S, Yu Z, Jayaraman M, Tran N, Li S BMC Cancer. 2019; 19(1):106.

PMID: 30691436 PMC: 6348625. DOI: 10.1186/s12885-019-5306-0.


Cooperativity Principles in Self-Assembled Nanomedicine.

Li Y, Wang Y, Huang G, Gao J Chem Rev. 2018; 118(11):5359-5391.

PMID: 29693377 PMC: 6524957. DOI: 10.1021/acs.chemrev.8b00195.